The investment process evaluates ESG in the context of risk and opportunities as a core part of the due diligence procedure that underpins every investment decision. To our mind, the most important ESG aspect of the medical development process is the potential positive impact novel therapeutics can have on society: the aspiration of the biotech companies in which we invest is to develop drugs that address unmet medical needs.
INVESTORS
Corporate Governance & responsable Investing
Corporate governance is an integral component to the business of BB Biotech AG (the Company). The Board of Directors is committed to implement corporate governance policies which are aligned with the size and complexity of the Company’s activities.
We ensure transparency for our shareholders by disclosing the articles of incorporation, the organizational regulations as well as the Audit & Risk Committee Charter, the Remuneration and Nomination Committee Charter and the Sustainability and Governance Committee Charter on our homepage. This report is intended to supplement the annual report with respect to corporate governance policies and implementation of these policies in our business. As BB Biotech AG is listed on the Swiss and German stock exchanges, the Company is required to comply with the rules and regulations that apply to each of these markets.
Corporate Governance Report
Governance & oversight
Governance framework
Board committees (Audit, Risk, Governance, Compensation) with brief explanation of role
Separation of governance and management functions
Bellevue Asset Management’s regulatory oversight (FINMA) and license status
What this means for investors
Depth of expertise: decades of combined experience across biotech, finance and corporate governance
Rigorous oversight: strategic governance supports disciplined investing
Scientific and financial integration: investment decisions informed by both disciplines
Stable leadership: continuity in board and investment management builds long-term confidence
Directors' Dealings
Notification concerning transactions by persons performing managerial responsibilities pursuant to Article 19 MAR
Transaction of BB Biotech AG (ISIN CH0038389992, par value of CHF 0.20), Schwertstrasse 6, CH-8200 Schaffhausen done by the Board of Directors, the Management or close associates of these persons are reported here.
Sustainability
